GoodRx (NASDAQ:GDRX - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $202.25 million for the quarter.
GoodRx Price Performance
GDRX stock traded up $0.04 during mid-day trading on Friday, reaching $4.68. The company's stock had a trading volume of 1,106,236 shares, compared to its average volume of 1,380,488. The stock has a market cap of $1.80 billion, a PE ratio of -156.00, a P/E/G ratio of 2.46 and a beta of 1.25. The company's 50 day moving average is $4.55 and its two-hundred day moving average is $4.83. GoodRx has a fifty-two week low of $3.82 and a fifty-two week high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.
Wall Street Analysts Forecast Growth
GDRX has been the topic of a number of recent research reports. Wells Fargo & Company lowered their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday. KeyCorp reduced their price target on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Truist Financial dropped their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a report on Thursday, April 10th. Finally, Citigroup reduced their target price on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research note on Friday, January 10th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $7.84.
View Our Latest Stock Report on GDRX
GoodRx Company Profile
(
Get Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Featured Stories
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
